Ziopharm Oncology (ZIOP) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (ZIOPResearch Report), with a price target of $6.50. The company’s shares closed last Monday at $5.21.

According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -5.0% and a 34.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ziopharm Oncology with a $6.50 average price target.

See today’s analyst top recommended stocks >>

Based on Ziopharm Oncology’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $74 million. In comparison, last year the company had a GAAP net loss of $12.59 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer.